The stock of Krystal Biotech, Inc. (NASDAQ:KRYS) is now priced at $44.75 and the shares are -0.73 points down or -1.61% lower compared to its previous closing price of $45.48. The stock had 112450 contracts set over the past session. KRYS shares’ daily volume is compared to its average trading volume at 199725 shares. However, it has a float of 14.19 million and although its performance was 5.15% over the week, it’s one to watch. KRYS share price recently placing at $44.39 to $46.73.
The shorts are climbing into the Krystal Biotech, Inc. stock, with the latest data on short interest released on June 15, 2020, showing that short interest numbers in the KRYS shares have risen. Short interest in the stock represents just 8.62% of its float, but the volume has raised by 46878. The volume of shorted shares rised to 1.223 million from 1.176 million shares over the last two weeks. The average intraday trading volume has been 119587 shares, which means that days to cover moved to roughly 10.229406.
In the last trading session, Krystal Biotech, Inc. (NASDAQ:KRYS) raised by $2.19 over the week and lost -$3.75 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $66.85. The stock recorded its established 52-week high on 02/13/20.
Since 10/02/19, the stock has traded to a low of $31.89 at 40.33%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 0. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.
Looking at current readings, Krystal Biotech, Inc.’s two-week RSI is 47.02. This suggests that the stock is neutral at the moment and that KRYS shares’ price movement remains stable. The stochastic readings are equally revealing at 31.21% meaning the KRYS share price is currently in neutral territory.
The technical chart shows that the KRYS stock will likely settle at between $46.19 and $47.63 per share. However, if the stock dips below $43.85, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $42.95.
Currently, the stock is trading in the green of MACD, with a reading of 0.47. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.
Analysts at Maxim Group assigned KRYS a rating of Outperform in their intiating review released on June 04. Goldman analysts see the stock as a Neutral with a target price of $60 in a flash note released to investors on September 24 initiating covering the stock. H.C. Wainwright analysts see the stock as Buy. Nonetheless, the analysts revised the share prices up on August 06, placing it at $59 from $56.
The average rating for the KRYS equity is 1.75 and is currently gathering a bullish momentum. Of 9 analysts tracking Krystal Biotech, Inc. polled by Reuters, 1 rated KRYS as a hold. The remaining 8 analysts were split evenly. However, the split wasn’t equal as a majority (8) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.